Menu Search
Equities

Neurizon Therapeutics Ltd

ECQ0:STU

Neurizon Therapeutics Ltd

Actions
  • Price (EUR)0.1128
  • Today's Change0.009 / 8.46%
  • Shares traded350.00
  • 1 Year change+142.58%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

  • Revenue in AUD (TTM)866.18k
  • Net income in AUD-8.90m
  • Incorporated2000
  • Employees52.00
  • Location
    Neurizon Therapeutics Ltd96-100 Albert Road, Level 4SOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 39692-7222
  • Fax+61 89467-6111
  • Websitehttps://www.pharmaust.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.